SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice

被引：0
|
作者：
John Wilding
Kevin Fernando
Nicola Milne
Marc Evans
Amar Ali
Steve Bain
Debbie Hicks
June James
Philip Newland-Jones
Dipesh Patel
Adie Viljoen
机构：
[1] University of Liverpool,Obesity and Endocrinology Research
[2] North Berwick Health Centre,Department of Diabetes
[3] CODES (COmmunity Diabetes Education and Support),Diabetes Research Unit Cymru
[4] University Hospital Llandough,Department of Diabetes and Endocrinology
[5] Oakenhurst Medical Practice,Department of Metabolic Medicine/Chemical Pathology
[6] Swansea University,undefined
[7] Barnet,undefined
[8] Enfield and Haringey Mental Health Trust,undefined
[9] University Hospitals of Leicester NHS Trust,undefined
[10] University Hospitals Southampton NHS Foundation Trust,undefined
[11] Royal Free NHS Foundation Trust,undefined
[12] Lister Hospital,undefined
来源：
Diabetes Therapy | 2018年 / 9卷
关键词：
Clinical guidance; Glucose-lowering medicines; Oral glucose-lowering medicines; Prescribing tools; Risk/benefit; SGLT2 inhibitors; Therapy choice; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1757 / 1773
页数：16
相关论文
共 50 条
  • [1] SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice
    Wilding, John
    Fernando, Kevin
    Milne, Nicola
    Evans, Marc
    Ali, Amar
    Bain, Steve
    Hicks, Debbie
    James, June
    Newland-Jones, Philip
    Patel, Dipesh
    Viljoen, Adie
    DIABETES THERAPY, 2018, 9 (05) : 1757 - 1773
  • [2] Living with Type 2 Diabetes: Patient Commentary in Response to the Paper ‘SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice’
    Marc Evans
    Diabetes Therapy, 2018, 9 : 1729 - 1732
  • [3] Living with Type 2 Diabetes: Patient Commentary in Response to the Paper 'SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice'
    Evans, Marc
    DIABETES THERAPY, 2018, 9 (05) : 1729 - 1732
  • [4] SGLT2 inhibitors in the management of type 2 diabetes
    R. P. Monica Reddy
    Silvio E. Inzucchi
    Endocrine, 2016, 53 : 364 - 372
  • [5] SGLT2 inhibitors in the management of type 2 diabetes
    Reddy, R. P. Monica
    Inzucchi, Silvio E.
    ENDOCRINE, 2016, 53 (02) : 364 - 372
  • [6] Clinical implication of SGLT2 inhibitors in type 2 diabetes
    Go Woon Kim
    Sung Hyun Chung
    Archives of Pharmacal Research, 2014, 37 : 957 - 966
  • [7] Clinical implication of SGLT2 inhibitors in type 2 diabetes
    Kim, Go Woon
    Chung, Sung Hyun
    ARCHIVES OF PHARMACAL RESEARCH, 2014, 37 (08) : 957 - 966
  • [8] SGLT2 Inhibitors for Type 2 Diabetes
    Liu, Jiwen
    Lee, TaeWeon
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 46, 2011, 46 : 103 - +
  • [9] SGLT2 inhibitors in clinical practice
    Ryden, Lars
    Norhammar, Anna
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (07): : 434 - 435
  • [10] Cardiovascular Risks With SGLT2 Inhibitors in Clinical Practice Among Patients With Type 2 Diabetes
    Su, Hsuan-Yu
    Yang, Chen-Yi
    Lee, Yu-Hsuan
    Su, Pei-Fang
    Liu, Yi-Chia
    Ou, Huang-Tz
    JAMA NETWORK OPEN, 2024, 7 (10)
12345